3rd Annual Atlanta Precision Oncology Symposium

 

3rd Annual Atlanta Precision Oncology Symposium
D

Targeted Therapies for Advanced Urothelial Cancer: Erdafitinib for Patients With FGFR3 Alterations, 3L Enfortumab Vedotin and IMMU-132

By 3rd Annual Atlanta Precision Oncology Symposium FEATURING Daniel Petrylak
By 3rd Annual Atlanta Precision Oncology Symposium FEATURING Daniel Petrylak
138 views
February 14, 2021
0 Comments
Login to view comments. Click here to Login

Featured Video

20:25
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam

Featured Video

21:09
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam
Videos
12:36
3rd Annual Atlanta Precision Oncology Symposium

Genotype-Directed Therapy for Advanced NSCLC: Overview of Targeted T…

Feat. H. Borghaei
26:48
3rd Annual Atlanta Precision Oncology Symposium

Targeted Therapies for Advanced Urothelial Cancer: Erdafitinib for P…

Feat. D. Petrylak
13:52
3rd Annual Atlanta Precision Oncology Symposium

Targeted Therapy for Advanced NSCLC: Efficacy Analysis of RET, KRAS,…

Feat. H. Borghaei
25:48
3rd Annual Atlanta Precision Oncology Symposium

2021 Expert Discussion on GU Cancers: Should We Use Olaparib Before …

Feat. E. Antonarakis, D. Petrylak, T. Zhang
26:48
3rd Annual Atlanta Precision Oncology Symposium

Treatment of DNA Repair-Deficient Advanced Prostate Cancer

Feat. E. Antonarakis
26:42
3rd Annual Atlanta Precision Oncology Symposium

2021 Expert Discussion on Advanced NSCLC: Is Osimertinib a Good Sequ…

Feat. E. Garon, N. Hanna, H. Borghaei, J. Kirkpatrick
23:13
3rd Annual Atlanta Precision Oncology Symposium

Early Detection of Lung Cancer: Molecular Enrichment Strategy

Feat. J. Kirkpatrick
18:36
3rd Annual Atlanta Precision Oncology Symposium

Selecting Systemic First-Line Treatment in Stage IV NSCLC Without Dr…

Feat. N. Hanna
20:20
3rd Annual Atlanta Precision Oncology Symposium

2021 Expert Discussion on BC: How to Preoperatively Manage TNBC? How…

Feat. I. Mayer, J. Litton, R. O’Regan
32:45
3rd Annual Atlanta Precision Oncology Symposium

2021 Updates on Systemic Therapy for TNBC: Why Should We Choose Neoa…

Feat. R. O’Regan
06:49
3rd Annual Atlanta Precision Oncology Symposium

IO for mTNBC: Overview of the Efficacy Data

Feat. J. Litton
13:30
3rd Annual Atlanta Precision Oncology Symposium

ADCs & Targeted Therapies for Advanced TNBC: Can Sacituzumab Gov…

Feat. J. Litton
09:52
3rd Annual Atlanta Precision Oncology Symposium

EGFR+ Advanced NSCLC: Should 1L Therapy Include an EGFR Inhibitor Re…

Feat. E. Garon
15:01
3rd Annual Atlanta Precision Oncology Symposium

EGFR+ Advanced NSCLC: Efficacy Data of TKIs in Combination vs. Alone…

Feat. E. Garon
05:55
3rd Annual Atlanta Precision Oncology Symposium

Sequence Algorithm for HER2+ Breast Cancer: Does Neratinib + Cape Ha…

Feat. I. Mayer
05:03
3rd Annual Atlanta Precision Oncology Symposium

CNS Metastases in HER2+ MBC: PFS Data on the Addition of Tucatinib t…

Feat. I. Mayer
17:47
3rd Annual Atlanta Precision Oncology Symposium

HER2+ MBC Sequencing Algorithm: Surveying the Data for Antibody-Drug…

Feat. I. Mayer
14:04
3rd Annual Atlanta Precision Oncology Symposium

[PRIVATE] Targeted Therapies for mRCC: Surveying Efficacy Data for I…

Feat. T. Zhang
17:05
3rd Annual Atlanta Precision Oncology Symposium

[PRIVATE] Targeted Therapies for mRCC: Assessing IMDC Risk Criteria …

Feat. T. Zhang
08:45
3rd Annual Atlanta Precision Oncology Symposium

Targeting Genetic Mutations in mNSCLC: Clinical Data Overview of RET…

Feat. H. Dilks